Invivyd Inc. | Micro-cap | Healthcare

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 11.8M
Gross Profit 11.1M 94.19%
Operating Income -15.1M -127.78%
Net Income -14.7M -124.38%
EPS (Diluted) $-0.12

Balance Sheet Metrics

Total Assets 103.7M
Total Liabilities 49.6M
Shareholders Equity 54.1M
Debt to Equity 0.92

Cash Flow Metrics

Operating Cash Flow -12.5M
Free Cash Flow -21.3M

Revenue & Profitability Trend

Invivyd Income Statement From 2021 to 2024

Metric2024202320222021
Revenue i25.4M000
Cost of Goods Sold i1.6M---
Gross Profit i23.8M---
Gross Margin % i93.6%0.0%0.0%0.0%
Operating Expenses
Research & Development i137.3M158.7M179.2M182.9M
Selling, General & Administrative i63.4M49.1M47.0M36.5M
Other Operating Expenses i----
Total Operating Expenses i200.6M207.8M226.3M219.4M
Operating Income i-176.9M-207.8M-226.3M-219.4M
Operating Margin % i-696.8%0.0%0.0%0.0%
Non-Operating Items
Interest Income i----
Interest Expense i----
Other Non-Operating Income7.0M9.1M-15.1M-7.4M
Pre-tax Income i-169.9M-198.6M-241.3M-226.8M
Income Tax i----
Effective Tax Rate % i0.0%0.0%0.0%0.0%
Net Income i-169.9M-198.6M-241.3M-226.8M
Net Margin % i-669.4%0.0%0.0%0.0%
Key Metrics
EBITDA i-173.8M-200.8M-204.0M-211.9M
EPS (Basic) i$-1.43$-1.81$-2.23$-5.32
EPS (Diluted) i$-1.43$-1.81$-2.23$-5.32
Basic Shares Outstanding i11855507310952605310826828942621265
Diluted Shares Outstanding i11855507310952605310826828942621265

Income Statement Trend

Invivyd Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i69.3M200.6M92.1M542.2M115.0M
Short-term Investments i-0279.9M49.2M0
Accounts Receivable i10.9M----
Inventory i-----
Other Current Assets----141.0K
Total Current Assets i100.7M224.9M376.9M616.7M117.4M
Non-Current Assets
Property, Plant & Equipment i2.9M4.1M6.1M83.0K-
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets25.9M175.0K191.0K3.3M-
Total Non-Current Assets i28.8M4.3M6.2M3.4M0
Total Assets i129.5M229.2M383.2M620.1M117.4M
Liabilities
Current Liabilities
Accounts Payable i10.4M8.0M1.5M5.8M8.2M
Short-term Debt i1.3M1.4M1.6M--
Current Portion of Long-term Debt-----
Other Current Liabilities27.0K35.0K44.0K--
Total Current Liabilities i62.0M50.3M25.0M62.1M13.1M
Non-Current Liabilities
Long-term Debt i0722.0K2.2M0-
Deferred Tax Liabilities i-----
Other Non-Current Liabilities-700.0K1.0K12.0K11.0K
Total Non-Current Liabilities i01.4M2.2M12.0K169.6M
Total Liabilities i62.0M51.7M27.2M62.1M182.6M
Equity
Common Stock i12.0K11.0K11.0K11.0K1.0K
Retained Earnings i-902.0M-732.1M-533.4M-292.1M-65.3M
Treasury Stock i000085.0K
Other Equity-----
Total Shareholders Equity i67.5M177.5M356.0M558.0M-65.2M
Key Metrics
Total Debt i1.3M2.2M3.7M00
Working Capital i38.7M174.6M351.9M554.7M104.3M

Balance Sheet Composition

Invivyd Cash Flow Statement From 2021 to 2024

Metric2024202320222021
Operating Activities
Net Income i-169.9M-198.6M-241.3M-226.8M
Depreciation & Amortization i3.1M2.0M462.0K1.0K
Stock-Based Compensation i19.8M18.7M21.6M17.8M
Working Capital Changes i-35.6M5.6M-1.6M-5.7M
Operating Cash Flow i-182.6M-172.3M-220.8M-214.6M
Investing Activities
Capital Expenditures i-140.0K-615.0K-1.7M-84.0K
Acquisitions i----
Investment Purchases i0-91.2M-298.0M-188.6M
Investment Sales i0372.5M69.0M138.0M
Investing Cash Flow i-140.0K280.7M-230.7M-50.7M
Financing Activities
Share Repurchases i0-1.0K-4.0K0
Dividends Paid i----
Debt Issuance i----
Debt Repayment i----
Financing Cash Flow i38.7M-150.0K-4.0K662.7M
Free Cash Flow i-170.6M-173.8M-221.7M-184.8M
Net Change in Cash i-144.1M108.2M-451.5M397.3M

Cash Flow Trend

Invivyd Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -0.80
Forward P/E -5.70
Price to Book 3.20
Price to Sales 5.17
PEG Ratio 0.01

Profitability Ratios

Profit Margin -238.33%
Operating Margin -127.78%
Return on Equity -120.08%
Return on Assets -53.25%

Financial Health

Current Ratio 1.33
Debt to Equity 6.93
Beta 0.55

Per Share Data

EPS (TTM) $-0.92
Book Value per Share $0.36
Revenue per Share $0.39

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
ivvd238.7M-0.803.20-120.08%-238.33%6.93
Vertex 101.6B28.195.9122.77%31.86%8.89
Regeneron 60.8B14.451.9915.34%31.37%9.04
Third Harmonic Bio 242.8M12.460.89-19.94%0.00%1.10
Tonix 241.9M0.011.19-77.51%23.07%0.29
Annexon 238.5M-2.151.20-66.75%0.00%13.88

Financial data is updated regularly. All figures are in the company's reporting currency.